German Regulator Hails EMA's Generic Drugs Suspension on GVK Bio Data

German drug regulator has hailed the European Medicine Agency's decision to suspend the marketing authorisation of more than 700 generic drugs subjected to clinical trials by India's GVK Biosciences.

The decision is being seen as the EU's determination to maintain high ethical and medical standards for approval of medicines.

Internet Strategies to Discredit Generic Drugs
The scientific community believes that the composition of generic drugs is identical to that of brand name drugs, however, the general public does not think so.

The EU drug regulator's announcement is also an endorsement of the Federal Institute for Drugs and Medical Devices' (BfArM) decision last month to ban the sale of 80 generic drugs on account of ‘substantial deficiencies’ in clinical trials.

The German watchdog said it would take a decision shortly on whether to add more medicines to the list of banned drugs in the wake of the EMA's announcement.

The agency based in Bonn had so far reviewed the marketing approvals of 176 generic drugs granted on the basis of clinical trial data provided by GVK Biosciences during the period between 2008 and 2014, the agency said in a statement.

The EU drug regulator on Friday suspended the marketing authorisation of around 700 generic drugs on the grounds that their approvals were supported by ‘flawed’ clinical trial data provided by the Indian company.

West Bengal Is Trying To Replace Branded Medicines With Generic Drugs
Generic drugs are being pushed in a big way by the West Bengal government to replace expensive branded medicines and bring down the prices of essential drugs.

Source-Medindia

Generic Drugs as Default in Electronic Health Records Reduces Unnecessary Spending in US Health Industry
According to a new study programming the electronic health records to make generic drugs as the default choice may offer one way to reduce unnecessary spending and improve health care value.